Kawasaki, Japan

Masako Uno

This inventor holds 1 USPTO granted patent. Top assignee: Teikoku Hormone Mfg. Co., Ltd.. Active years: 1989.


% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 1989

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Masako Uno: A Pioneer in Antihypertensive Agents

Introduction

Masako Uno is an accomplished inventor based in Kawasaki, Japan, recognized for her significant contributions to the pharmaceutical field. Her innovative spirit and dedication have led to the development of essential compounds aimed at improving health outcomes.

Latest Patents

Masako Uno holds a patent for "Antihypertensive pyridazinone aminoisopropanol derivatives." This patent describes a pyridazinone derivative that features a general formula allowing for various configurations of substituent groups. The compounds derived from her invention are useful as antihypertensive agents, providing vital treatment options for managing high blood pressure.

Career Highlights

Uno's career is marked by her work at Teikoku Hormone Manufacturing Co., Ltd., where her research and development efforts focus on innovative pharmaceutical solutions. Her background in chemistry and dedication to her work have made her a valuable asset to the company.

Collaborations

Throughout her career, Masako Uno has collaborated with esteemed colleagues such as Kikuo Yasuda and Kenyu Shibata. These partnerships showcase her ability to work effectively within a team, contributing to the overall success of various projects aimed at advancing medical science.

Conclusion

Masako Uno's contributions to the field of pharmacology, particularly through her patent for antihypertensive compounds, illustrate her role as a pioneer inventor. Her work not only highlights her dedication but also her commitment to improving health and wellness through innovative science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…